These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 23052187

  • 1. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
    Bodmann KF, Heizmann WR, von Eiff C, Petrik C, Löschmann PA, Eckmann C.
    Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187
    [Abstract] [Full Text] [Related]

  • 2. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
    Guirao X, Sánchez García M, Bassetti M, Bodmann KF, Dupont H, Montravers P, Heizmann WR, Capparella MR, Simoneau D, Eckmann C.
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
    [Abstract] [Full Text] [Related]

  • 3. Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.
    Heizmann WR, Dupont H, Montravers P, Guirao X, Eckmann C, Bassetti M, García MS, Capparella MR, Simoneau D, Bodmann KF.
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii45-55. PubMed ID: 23772046
    [Abstract] [Full Text] [Related]

  • 4. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice.
    Eckmann C, Heizmann WR, Leitner E, von Eiff C, Bodmann KF.
    Chemotherapy; 2011 Jul; 57(4):275-84. PubMed ID: 21778715
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies.
    Montravers P, Bassetti M, Dupont H, Eckmann C, Heizmann WR, Guirao X, García MS, Capparella MR, Simoneau D, Bodmann KF.
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii15-24. PubMed ID: 23772042
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.
    Eckmann C, Montravers P, Bassetti M, Bodmann KF, Heizmann WR, Sánchez García M, Guirao X, Capparella MR, Simoneau D, Dupont H.
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii25-35. PubMed ID: 23772043
    [Abstract] [Full Text] [Related]

  • 7. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria.
    Heizmann WR, Löschmann PA, Eckmann C, von Eiff C, Bodmann KF, Petrik C.
    Infection; 2015 Feb; 43(1):37-43. PubMed ID: 25367409
    [Abstract] [Full Text] [Related]

  • 8. Tigecycline in the Treatment of Patients with Necrotizing Skin and Soft Tissue Infections Due to Multiresistant Bacteria.
    Eckmann C, Heizmann W, Bodmann KF, von Eiff C, Petrik C, Loeschmann PA.
    Surg Infect (Larchmt); 2015 Oct; 16(5):618-25. PubMed ID: 26115414
    [Abstract] [Full Text] [Related]

  • 9. Tigecycline: an update.
    Stein GE, Babinchak T.
    Diagn Microbiol Infect Dis; 2013 Apr; 75(4):331-6. PubMed ID: 23357291
    [Abstract] [Full Text] [Related]

  • 10. Clinical and microbiological efficacy of tigecycline for complicated skin-soft-tissue and intra-abdominal infections in a Turkish university hospital.
    Avkan-Oguz V, Yapar N, Alp-Cavus S, Demir Onder K, Aktas E, Gulay Z, Cakır N.
    Int J Clin Pract; 2013 Jun; 67(6):505-11. PubMed ID: 23679904
    [Abstract] [Full Text] [Related]

  • 11. Clinical response and mortality in tigecycline complicated intra-abdominal infection and complicated skin and soft-tissue infection trials.
    Bassetti M, McGovern PC, Wenisch C, Meyer RD, Yan JL, Wible M, Rottinghaus ST, Quintana A.
    Int J Antimicrob Agents; 2015 Sep; 46(3):346-50. PubMed ID: 26155003
    [Abstract] [Full Text] [Related]

  • 12. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
    Bassetti M, Eckmann C, Bodmann KF, Dupont H, Heizmann WR, Montravers P, Guirao X, Capparella MR, Simoneau D, Sánchez García M.
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
    Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, Dukart G, Babinchak T, Cooper CA, Ellis-Grosse EJ, Dartois N, Gandjini H, 307 Study Group.
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
    [Abstract] [Full Text] [Related]

  • 14. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E, 309 Study Group.
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [Abstract] [Full Text] [Related]

  • 15. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ.
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA, Weaver-Sands DT, Petersen PJ.
    Clin Infect Dis; 2005 Sep 01; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
    Grolman DC.
    Int J Infect Dis; 2007 May 01; 11 Suppl 1():S7-15. PubMed ID: 17603950
    [Abstract] [Full Text] [Related]

  • 18. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE, Rybak MJ.
    Pharmacotherapy; 2006 Aug 01; 26(8):1099-110. PubMed ID: 16863487
    [Abstract] [Full Text] [Related]

  • 19. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit.
    Swoboda S, Ober M, Hainer C, Lichtenstern C, Seiler C, Wendt C, Hoppe-Tichy T, Büchler M, Weigand MA.
    J Antimicrob Chemother; 2008 Mar 01; 61(3):729-33. PubMed ID: 18222953
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012.
    Renteria MI, Biedenbach DJ, Bouchillon SK, Hoban DJ, Raghubir N, Sajben P, Mokaddas E.
    Diagn Microbiol Infect Dis; 2014 May 01; 79(1):54-9. PubMed ID: 24582580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.